Jan. 19 Sun Pharma states Organon acquisition news is speculative RE
Jan. 16 Sun Pharma Announces the Availability of UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma AQ
Jan. 15 Sun Pharmaceutical Industries Limited Announces the Availability of UNLOXCYT (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma CI
Jan. 07 Sun Pharma Canada Inc. Announces Availability Of ILUMYA Pen For Moderate-To-Severe Plaque Psoriasis CI
Jan. 02 Sun Pharma Launches ILUMYA® In India AQ
Dec. 23 Lilly, Novo lock horns in India's obesity drug race RE
Dec. 18 Indian Equities Post Marginal Loss on Thursday as Consolidation Continues MT
Dec. 17 Sun Pharmaceutical's Baska Facility Receives 'Official Action Indicated' Status From US FDA MT
Dec. 17 Sun Pharma says US FDA determines Baska facility inspection classification as OAI RE
Dec. 12 Indian Stocks Extend Gains on Friday as Global Sentiment Improves After US Rate Cut MT
Dec. 12 Ozempic launches in India at $24 a week as Novo targets booming diabetes market RE
Dec. 03 Novo Nordisk gears up for December Ozempic launch in India, sources say RE
Dec. 01 Sun Pharma introduces its global innovative drug, Ilumya in India for treatment of moderate-to-severe Plaque Psoriasis AQ
Dec. 01 Sun Pharmaceutical Launches Plaque Psoriasis Drug in India MT
Nov. 30 Sun Pharma introduces Ilumya in India RE
Nov. 30 Sun Pharma Introduces Its Global Innovative Drug, Ilumya in India for Treatment of Moderate-To-Severe Plaque Psoriasis CI
Nov. 28 Indian Equities Ended Flat on Friday Ahead of Q2 GDP Data MT
Nov. 26 Sun Pharma says FDA approves label update for Unloxcyt RE
Nov. 25 Sun Pharmaceutical Industries Limited Announces Updated Label for Unloxcyt? CI
Nov. 17 AstraZeneca Pharma India, Sun Pharma Sign Second Brand Deal for SZC in India MT
Nov. 17 Astrazeneca Pharma India and Sun Pharma partner for hyperkalaemia treatment RE
Nov. 17 AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited Announce Partnership to Help Patients Living with Hyperkalaemia in India CI
Nov. 12 Sun Pharma presents data from phase 1b/2a study of GL0034 RE
Nov. 12 Sun Pharma says once weekly utregrlutide dosing for ten weeks showed body weight loss of 6.8% RE
Nov. 12 Sun Pharmaceutical Industries Limited Presents Data from Phase 1b/2a Study of GL0034 at the American Heart Association 2025 Scientific Sessions CI
No results for this search
  1. Stock Market
  2. Equities
  3. SUNPHARMA Stock
  4. News Sun Pharmaceutical Industries Ltd.